Gilead Sciences Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Well, great. Good afternoon, everybody. Thanks for joining us for the next session. I'm Matthew Harrison, one of the biopharma analysts here at Morgan Stanley.
Quickly before we get started, I need to read a disclosure statement. Please note that all important disclosures, including personal holdings disclosures and Morgan Stanley disclosures appear on the Morgan Stanley public website at morganstanley.com/researchdisclosures.
So pleased to have Gilead with us next, and Dan O'Day, the CEO.
Questions & Answers
Dan, I thought maybe a good place to start is just a couple macro items that come up a lot and maybe aren't even Gilead specific, but sort of industry specific. There remains a lot of uncertainty about what's happening in D.C. And I think none of us really know what's happening with reconciliation or otherwise.
'
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
